EXOZ
eXoZymes, Inc.NASDAQHealthcare$8.74+14.99%ClosedMarket Cap: $73.3M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
24.79
P/S
0.00
EV/EBITDA
0.00
DCF Value
$0.14
FCF Yield
-7.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-147.2%
ROA
-153.4%
ROIC
-203.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-2.7M | $-0.32 |
| FY 2025 | $0.00 | $-9.2M | $-1.09 |
| Q3 2025 | $0.00 | $-2.3M | $-0.27 |
| Q2 2025 | $0.00 | $-2.4M | $-0.28 |
Trading Activity
Insider Trades
View AllHeltzen Michaelofficer: Chief Executive Officer
BuyWed Jul 02
Heltzen Michaelofficer: Chief Executive Officer
SellFri Jun 20
Korman Tyler Pazofficer: Vice President, Research
SellTue Jun 17
Opgenorth Paul Hideoofficer: Vice President, Development
SellTue Jun 17
Nawaz Fouadofficer: Vice President, Finance
SellTue Jun 17
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.55
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.